Hydrogel systems for targeted cancer therapy

Frontiers in Bioengineering and Biotechnology, Год журнала: 2023, Номер 11

Опубликована: Фев. 16, 2023

When hydrogel materials with excellent biocompatibility and biodegradability are used as new drug carriers in the treatment of cancer, they confer following three advantages. First, can be a precise controlled release systems, which continuously sequentially chemotherapeutic drugs, radionuclides, immunosuppressants, hyperthermia agents, phototherapy agents other substances widely cancer through radiotherapy, chemotherapy, immunotherapy, hyperthermia, photodynamic therapy photothermal therapy. Second, have multiple sizes delivery routes, targeted to different locations types cancer. This greatly improves targeting thereby reducing dose drugs improving effectiveness. Finally, intelligently respond environmental changes according internal external stimuli so that anti-cancer active remotely released on demand. Combining abovementioned advantages, transformed into hit field treatment, bringing hope further increase survival rate quality life patients

Язык: Английский

---

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Advanced Science, Год журнала: 2023, Номер 10(18)

Опубликована: Апрель 23, 2023

Dendritic cell (DC)-based cancer immunotherapy has exhibited remarkable clinical prospects because DCs play a central role in initiating and regulating adaptive immune responses. However, the application of traditional DC-mediated is limited due to insufficient antigen delivery, inadequate presentation, high levels immunosuppression. To address these challenges, engineered biomaterials have been exploited enhance immunotherapeutic effects. In this review, vital principal components that can effects are first introduced. The parameters considered rational design biomaterials, including targeting modifications, size, shape, surface, mechanical properties, which affect biomaterial optimization DC functions, further summarized. Moreover, recent applications various field reviewed, those serve as component delivery platforms, remodel tumor microenvironment, synergistically other antitumor therapies. Overall, present review comprehensively systematically summarizes related promotion functions; specifically focuses on advances designs for activation eradicate tumors. challenges opportunities treatment strategies designed amplify via discussed with aim inspiring translation future immunotherapies.

Язык: Английский

---

Metabolic Intervention Liposome Boosted Lung Cancer Radio‐Immunotherapy via Hypoxia Amelioration and PD‐L1 Restraint

Advanced Science, Год журнала: 2023, Номер 10(18)

Опубликована: Апрель 24, 2023

At present, radiotherapy (RT) still acquires limited success in clinical due to the lessened DNA damage under hypoxia and acquired immune tolerance owing amplified programmed death ligand-1 (PD-L1) expression. Incredibly, intracellular PD-L1 expression depression is proven better sensitize RT by inhibiting repair. However, disability of clinically used antibodies disrupting extracellular PD-L1function limits effectiveness radio-immunotherapy. Therefore, regulation strategies are urgently needed Hence, for this purpose, TPP-LND synthesized linking mitochondrial-targeted triphenylphosphine cations (TPP+ ) antineoplastic agent lonidamine (LND), which significantly reduces dose LND induce effective oxidative phosphorylation inhibition (2 vs 300 µM). Then, wrapped with liposomes form TPP-LND@Lip nanoparticles. By doing this, nanoparticles can reversing hypoxic microenvironment tumors generate more reducing via enhancing adenosine 5'-monophosphate-activated protein kinase activation. As expected, these well-designed economical than conventional anti-PD-L1 some extent.

Язык: Английский

---

A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance

Advanced Materials, Год журнала: 2024, Номер 36(15)

Опубликована: Янв. 17, 2024

Abstract Currently, certain cancer patients exhibit resistance to radiotherapy due reduced DNA damage under hypoxic conditions and acquired immune tolerance triggered by transforming growth factor‐β1 (TGF‐β1) membrane‐localized programmed death ligand‐1 (PD‐L1). Meanwhile, cytoplasm‐distributed PD‐L1 induces through accelerating repair (DDR). However, the disability of clinically used antibodies in inhibiting limits their effectiveness. Therefore, a nanoadjuvant is developed sensitize via multi‐level immunity activation depressing TGF‐β1 triphenylphosphine‐derived metformin, activating cGAS‐STING pathway generating Mn 2+ from MnO 2 producing more dsDNA reversing tumor hypoxia impairing DDR. Thus, Tpp‐Met@MnO @Alb effectively enhances efficiency inhibit progression irradiated local abscopal tumors lung metastases, offering long‐term memory antitumor without discernible side effects. Overall, has potential be applied for overcoming radio‐immunotherapy resistance.

Язык: Английский

---

Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer

Bioactive Materials, Год журнала: 2024, Номер 39, С. 206 - 223

Опубликована: Май 21, 2024

Traditional treatments against advanced non-small cell lung cancer (NSCLC) with high morbidity and mortality continue to be dissatisfactory. Given this situation, there is an urgent requirement for alternative modalities that provide lower invasiveness, superior clinical effectiveness, minimal adverse effects. The combination of photodynamic therapy (PDT) immunotherapy gradually become a promising approach high-grade malignant NSCLC. Nevertheless, owing the absence precise drug delivery techniques as well hypoxic immunosuppressive characteristics tumor microenvironment (TME), efficacy less than ideal. In study, we construct novel nanoplatform indocyanine green (ICG), photosensitizer, loads into hollow manganese dioxide (MnO

Язык: Английский

---

Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis

Advanced Science, Год журнала: 2024, Номер 11(26)

Опубликована: Май 7, 2024

Abstract Currently, the typical combination therapy of programmed death ligand‐1 (PD‐L1) antibodies with radiotherapy (RT) still exhibits impaired immunogenic antitumor response in clinical due to lessened DNA damage and acquired immune tolerance via upregulation some other checkpoint inhibitors. Apart from this, such may raise occurrence rate radiation‐induced lung fibrosis (RIPF) enhanced systemic inflammation, leading ultimate cancer patients (average survival time about 3 years). Therefore, it is newly revealed that mitochondria energy metabolism regulation can be used as a novel effective PD‐L1 transforming growth factor‐β (TGF‐β) dual‐downregulation method. Following IR‐TAM prepared by conjugating mitochondria‐targeted heptamethine cyanine dye IR‐68 oxidative phosphorylation (OXPHOS) inhibitor Tamoxifen (TAM), which then self‐assembled albumin (Alb) form IR‐TAM@Alb nanoparticles. By doing tumor‐targeting nanoparticle effectively reversed tumor hypoxia depressed TGF‐β expression sensitize RT. Meanwhile, capacity targeting RIPF function TAM depressing TGF‐β, also ameliorated development induced

Язык: Английский

---

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Journal of Controlled Release, Год журнала: 2024, Номер 368, С. 233 - 250

Опубликована: Фев. 29, 2024

Язык: Английский

---

Dual‐Responsive Supramolecular Polymeric Nanomedicine for Self‐Cascade Amplified Cancer Immunotherapy

Advanced Science, Год журнала: 2024, Номер 11(20)

Опубликована: Март 17, 2024

Abstract Insufficient tumor immunogenicity and immune escape from tumors remain common problems in all immunotherapies. Recent studies have shown that pyroptosis, a form of programmed cell death is accompanied by checkpoint inhibitors, can induce effective immunogenic long‐term activation. Therapeutic strategies to jointly pyroptosis reverse immunosuppressive microenvironments are promising for cancer immunotherapy. In this regard, dual‐responsive supramolecular polymeric nanomedicine (NCSNPs) self‐cascade amplify the benefits immunotherapy designed. The NCSNPs formulated β‐cyclodextrin coupling nitric oxide (NO) donor, activator, NLG919, an indoleamine 2,3‐dioxygenase (IDO) inhibitor, self‐assembled through host–guest molecular recognition hydrophobic interaction obtain nanoparticles. possess excellent accumulation bioavailability attributed ingenious engineering. study not only confirms occurrence NO‐triggered first time but also reverses microenvironment sites via IDO inhibitor enhancing infiltration cytotoxic T lymphocytes, achieve remarkable inhibition proliferation. Thus, provides novel strategy

Язык: Английский

---

Mitochondria‐Targeted Nanoadjuvants Induced Multi‐Functional Immune‐Microenvironment Remodeling to Sensitize Tumor Radio‐Immunotherapy

Advanced Science, Год журнала: 2024, Номер 11(26)

Опубликована: Май 5, 2024

Abstract It is newly revealed that collagen works as a physical barrier to tumor immune infiltration, oxygen perfusion, and depressor in solid tumors. Meanwhile, after radiotherapy (RT), the programmed death ligand‐1 (PD‐L1) overexpression transforming growth factor‐β (TGF‐β) excessive secretion would accelerate DNA damage repair trigger T cell exclusion limit RT efficacy. However, existing drugs or nanoparticles can hardly address these obstacles of highly effective simultaneously, effectively, easily. In this study, it inducing mitochondria dysfunction by using oxidative phosphorylation inhibitors like Lonidamine (LND) serve multi‐immune pathway regulation strategy through PD‐L1, collagen, TGF‐β co‐depression. Then, IR‐LND prepared combining mitochondria‐targeted molecule IR‐68 with LND, which then loaded liposomes (Lip) create IR‐LND@Lip nanoadjuvants. By doing this, more effectively sensitizes generating cold tumors into hot ones activation co‐inhibition. conclusion, combined treatment ultimately almost completely suppressed bladder breast

Язык: Английский

---

Physical strategies to engineer supramolecular composite hydrogels for advanced biomedical applications

Progress in Materials Science, Год журнала: 2025, Номер 151, С. 101428 - 101428

Опубликована: Янв. 9, 2025

Язык: Английский

---